Results 241 to 250 of about 3,066,252 (313)

Seronegative Granulomatous Myositis With Bulbar Weakness and Reversible Cardiomyopathy: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT A 64‐year‐old woman presented with seronegative idiopathic granulomatous myositis, featuring severe bulbar weakness, reversible cardiomyopathy (ejection fraction 20%–25%), hepatic injury, and acute kidney injury. Muscle biopsy confirmed granulomatous inflammation.
Balachandran R. Vaidyanathan   +2 more
wiley   +1 more source

Nomenclature for Factors of the HLA System, 2026. [PDF]

open access: yesHLA
Marsh SGE   +14 more
europepmc   +1 more source

CCR2/CCR5 Signaling Defines a Pathogenic Interstitial Macrophage Subset That Drives Severe Asthma

open access: yesClinical and Translational Allergy, Volume 16, Issue 9, September 2026.
In mouse model of severe asthma, protective resident alveolar macrophages are depleted and replaced by monocyte‐derived populations, particularly a Lyve1loMHCIIhi interstitial macrophage subset enriched for Ccr2/Ccr5 and inflammatory gene programs. Blocking this subset with a dual CCR2/CCR5 antagonist reduces airway inflammation, restores homeostasis ...
Hao Wang   +8 more
wiley   +1 more source

Parallel processing of T cells and natural killer cells to enhance in vivo CAR T cell activity against blood and solid cancers

open access: yesClinical &Translational Immunology, Volume 15, Issue 9, 2026.
Abstract Objectives Despite their anti‐cancer properties, natural killer (NK) cells are discarded during CAR T cell manufacturing. NK cells display promising responses as a cell therapy, exhibiting remarkable safety at high doses. Moreover, NK cells have complementary cytokine profiles and distinct antigen‐recognition pathways to supplement CAR T cell ...
Lachlan J Dobson   +7 more
wiley   +1 more source

An Immunoinformatic Approach for a Multi-Epitope Vaccine Against Toxoplasma gondii. [PDF]

open access: yesParasite Immunol
Asadi N   +7 more
europepmc   +1 more source

B‐Cell Remodeling and Regulatory Phenotypes During Acute COVID‐19 Are Unaffected by Polyclonal Anti‐SARS‐CoV‐2 Antibody XAV‐19

open access: yesEuropean Journal of Immunology, Volume 56, Issue 9, September 2026.
SARS‐CoV‐2 infection drives transient B‐cell remodeling toward an activated, regulatory‐like phenotype. In this randomized sub‐study, the polyclonal neutralizing antibody XAV‐19 did not detectably alter B‐cell phenotype, transcriptome, or function relative to placebo, indicating that passive polyclonal therapy preserves B‐cell homeostasis during acute ...
Nicolas Degauque   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy